REGN
REGENERON PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$930.67
−4.39%Year over year
Reported trailing growth
- Revenue
- +18.6%
- EBITDA
- +9.3%
- EBIT
- +35.3%
- EPS
- +8.1%
- Free cash flow
- -13.6%
- Operating cash flow
- -9.1%
Forward estimates
Based on analyst estimates
- Revenue
- +23.7%
- EBITDA
- +60.4%
- EPS
- +70.3%
Three-year CAGR
- Revenue
- +5.6%
- EBITDA
- +3.4%
- EBIT
- -12.7%
- Net income
- +1.3%
- EPS
- +2.1%
- Free cash flow
- -2.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026